Exploring how antibody sequences work at the single-cell level using new technology
Official title: Linking antibody sequences to function at the single-cell level using nanovial technology
Funded at Partillion Bioscience Corporation · NIH-10928715 · Data updated 2026-11-12
This study is testing a new technology that helps scientists look closely at how individual antibodies work, which could lead to quicker and better treatments for diseases like autoimmune disorders and cancer, ultimately helping patients get the right therapies faster.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 16, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $731,568 |
| NIH project number | 5R44GM144000-03 |
| Project ID | NIH-10928715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with autoimmune diseases or cancers who may benefit from novel antibody treatments.
✕Less likely to help
Patients who do not have conditions that can be treated with monoclonal antibodies may not receive any benefit from this research.
What this research studies
This research focuses on developing a novel technology called nanovials that allows scientists to analyze the function of antibodies at the single-cell level. By using this advanced method, researchers can sort and study individual antibody-secreting cells based on how well their antibodies bind to specific targets. This approach aims to improve the efficiency of antibody discovery, making it easier for labs to identify effective treatments for various diseases, including autoimmune disorders and cancers. Patients may benefit from faster development of new antibody therapies that are tailored to their specific conditions.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and personalized antibody therapies for patients.
How similar studies have gone: Other research has shown success with similar high-throughput antibody discovery technologies, indicating a promising avenue for further exploration.
Where this research is happening
-
Partillion Bioscience Corporation
Los Angeles, United States Active
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
Related research
Other NIH-funded projects on the same topics.
-
Nanovial tools to map how single cells talk to each other at scale
New technology to study how individual cells communicate and affect each other, using easy-to-use nanovial kits with common single-cell sequencing methods.
-
Accelerating antibody discovery using memory B cells
A new program aims to speed up finding useful monoclonal antibodies by leveraging memory B cells with innovative tools to sort and test many cells at once.
-
Multiplexed antibody discovery using single-cell Nanovials
A patient-friendly look at a new method to speed up creating monoclonal antibodies by analyzing individual antibody-secreting cells more efficiently.
-
Improving the discovery of effective antibody therapies
This study is working on a faster and easier way to find important proteins called monoclonal antibodies, which help create better treatments for patients, so you can get more effective therapies more quickly and at a lower cost.
-
Using hydrogel microparticles to improve CAR-T cell therapies for cancer treatment
This study is working on improving CAR-T cell therapies for cancer by using special technology to find the best CAR-T cells that can fight tumors, which could lead to better treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.